We are analyzing https://link.springer.com/article/10.1007/s00262-019-02310-2.

Title:
Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors | Cancer Immunology, Immunotherapy
Description:
Immune checkpoint inhibitors (ICIs) targeting the programmed cell death-1 (PD-1)–programmed cell death ligand-1 (PD-L1) axis have shown promising results in non-small cell lung cancer (NSCLC) patients, some of them with persistent responses to these agents that form a population of long-term survivors. Despite the variable definition of PD-L1 positivity in tumors, an association between expression and response has been reasonably consistent in advanced NSCLC. In addition, the clinical efficacy of ICIs seems to be related to the genomic landscape of the tumor in terms of mutational burden and clonal neoantigens. Furthermore, increasing evidence shows that excessive activation of the immune response elicited by ICIs, leading to immune-related toxicities, might be associated with an improved response to immunotherapy. There are still many unanswered questions about the proper use of these agents to maximize their efficacy, which may be improved through combination with radiation, chemotherapy, targeted therapies, or other immune mediators, including dual checkpoint blockade. To search for clues for addressing these challenges, this review focused on the characteristics and clinical features of long-term NSCLC survivors and the potential biomarkers of response to ICIs.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Education
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,626,182 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't figure out the monetization strategy.

Not all websites are made for profit; some exist to inform or educate users. Or any other reason why people make websites. And this might be the case. Link.springer.com might be cashing in, but we can't detect the method they're using.

Keywords {🔍}

cancer, pubmed, article, google, scholar, lung, cas, oncol, cell, advanced, patients, nonsmall, nsclc, central, nonsmallcell, nivolumab, clin, immune, treated, study, immunotherapy, checkpoint, longterm, survival, response, clinical, treatment, phase, thorac, inhibitors, tumor, med, pembrolizumab, oncology, ann, survivors, pdl, efficacy, hellmann, blockade, metastatic, engl, nadal, icis, association, access, adverse, docetaxel, atezolizumab, previously,

Topics {✒️}

pd-1/pd-l1 targeted therapies anti-pd-l1 therapeutic strategies anti-pd-1/pd-l1 antibodies month download article/chapter anti-pd-1/pd-l1 agents small-cell lung cancer antibody-mediated thyroid dysfunction immune-mediated adverse events article cancer immunology immune-related adverse events t-cell checkpoint blockade gov/statfacts/html/lungb pd-1/pd-l1 axis carboplatin-paclitaxel/nab-paclitaxel pd-l1-expressing nsclc platinum-based doublet chemotherapy pd-l1—selected patients long-term nsclc survivors section “long-term survival rosario garcía-campelo full article pdf generalitat de catalunya programmed cell death-1 immune checkpoint inhibitors privacy choices/manage cookies immune checkpoint antibodies long-term survivors open-label keynote-021 study lung cancer statistics lung cancer immunotherapy pd-l1 positivity pd-l1 pathway pd-l1 expression pd-l1 status de lima lopes de mello ra long-term survival long-term survival” tumor mutational burden pd-1 axis inhibitors immune checkpoint blockade targeted therapies tumor immune infiltration future therapeutic combinations” squamous lung cancer md reviewed evidence immune parameters affecting human cancer immunotherapy cancer stat facts anti-pd-1 treatment

Questions {❓}

Marshall R, Popple A, Kordbacheh T, Honeychurch J, Faivre-Finn C, Illidge T (2017) Immune checkpoint inhibitors in lung cancer—an unheralded opportunity?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors
         description:Immune checkpoint inhibitors (ICIs) targeting the programmed cell death-1 (PD-1)–programmed cell death ligand-1 (PD-L1) axis have shown promising results in non-small cell lung cancer (NSCLC) patients, some of them with persistent responses to these agents that form a population of long-term survivors. Despite the variable definition of PD-L1 positivity in tumors, an association between expression and response has been reasonably consistent in advanced NSCLC. In addition, the clinical efficacy of ICIs seems to be related to the genomic landscape of the tumor in terms of mutational burden and clonal neoantigens. Furthermore, increasing evidence shows that excessive activation of the immune response elicited by ICIs, leading to immune-related toxicities, might be associated with an improved response to immunotherapy. There are still many unanswered questions about the proper use of these agents to maximize their efficacy, which may be improved through combination with radiation, chemotherapy, targeted therapies, or other immune mediators, including dual checkpoint blockade. To search for clues for addressing these challenges, this review focused on the characteristics and clinical features of long-term NSCLC survivors and the potential biomarkers of response to ICIs.
         datePublished:2019-02-06T00:00:00Z
         dateModified:2019-02-06T00:00:00Z
         pageStart:341
         pageEnd:352
         sameAs:https://doi.org/10.1007/s00262-019-02310-2
         keywords:
            Biomarker
            Immune checkpoint inhibitors
            Immunotherapy
            Long-term survival
            Non-small cell lung cancer
            PD-L1
            Oncology
            Immunology
            Cancer Research
         image:
         isPartOf:
            name:Cancer Immunology, Immunotherapy
            issn:
               1432-0851
               0340-7004
            volumeNumber:68
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Berlin Heidelberg
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Ernest Nadal
               url:http://orcid.org/0000-0002-9674-5554
               affiliation:
                     name:Catalan Institute of Oncology (ICO)
                     address:
                        name:Department of Medical Oncology, Catalan Institute of Oncology (ICO), Barcelona, Spain
                        type:PostalAddress
                     type:Organization
                     name:IDIBELL
                     address:
                        name:Clinical Research in Solid Tumors (CReST) Group, OncoBell Program, IDIBELL, Barcelona, Spain
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Bartomeu Massuti
               affiliation:
                     name:Hospital Universitario de Alicante, ISABIAL
                     address:
                        name:Department of Medical Oncology, Hospital Universitario de Alicante, ISABIAL, Alicante, Spain
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Manuel Dómine
               affiliation:
                     name:Hospital Universitario Fundación Jiménez Díaz, Oncohealth Institute, Universidad Autónoma de Madrid
                     address:
                        name:Department of Medical Oncology, Hospital Universitario Fundación Jiménez Díaz, Oncohealth Institute, Universidad Autónoma de Madrid, Madrid, Spain
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Rosario García-Campelo
               affiliation:
                     name:A Coruña University Hospital
                     address:
                        name:Department of Medical Oncology, A Coruña University Hospital, A Coruña, Spain
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Manuel Cobo
               affiliation:
                     name:Hospital Universitario Málaga Regional y Virgen de la Victoria, IBIMA
                     address:
                        name:Medical Oncology Department, Hospital Universitario Málaga Regional y Virgen de la Victoria, IBIMA, Málaga, Spain
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Enriqueta Felip
               affiliation:
                     name:Hospital Universitari Vall d’Hebron and Vall d’Hebron Institute of Oncology (VHIO)
                     address:
                        name:Lung Cancer Unit, Hospital Universitari Vall d’Hebron and Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors
      description:Immune checkpoint inhibitors (ICIs) targeting the programmed cell death-1 (PD-1)–programmed cell death ligand-1 (PD-L1) axis have shown promising results in non-small cell lung cancer (NSCLC) patients, some of them with persistent responses to these agents that form a population of long-term survivors. Despite the variable definition of PD-L1 positivity in tumors, an association between expression and response has been reasonably consistent in advanced NSCLC. In addition, the clinical efficacy of ICIs seems to be related to the genomic landscape of the tumor in terms of mutational burden and clonal neoantigens. Furthermore, increasing evidence shows that excessive activation of the immune response elicited by ICIs, leading to immune-related toxicities, might be associated with an improved response to immunotherapy. There are still many unanswered questions about the proper use of these agents to maximize their efficacy, which may be improved through combination with radiation, chemotherapy, targeted therapies, or other immune mediators, including dual checkpoint blockade. To search for clues for addressing these challenges, this review focused on the characteristics and clinical features of long-term NSCLC survivors and the potential biomarkers of response to ICIs.
      datePublished:2019-02-06T00:00:00Z
      dateModified:2019-02-06T00:00:00Z
      pageStart:341
      pageEnd:352
      sameAs:https://doi.org/10.1007/s00262-019-02310-2
      keywords:
         Biomarker
         Immune checkpoint inhibitors
         Immunotherapy
         Long-term survival
         Non-small cell lung cancer
         PD-L1
         Oncology
         Immunology
         Cancer Research
      image:
      isPartOf:
         name:Cancer Immunology, Immunotherapy
         issn:
            1432-0851
            0340-7004
         volumeNumber:68
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Berlin Heidelberg
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Ernest Nadal
            url:http://orcid.org/0000-0002-9674-5554
            affiliation:
                  name:Catalan Institute of Oncology (ICO)
                  address:
                     name:Department of Medical Oncology, Catalan Institute of Oncology (ICO), Barcelona, Spain
                     type:PostalAddress
                  type:Organization
                  name:IDIBELL
                  address:
                     name:Clinical Research in Solid Tumors (CReST) Group, OncoBell Program, IDIBELL, Barcelona, Spain
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Bartomeu Massuti
            affiliation:
                  name:Hospital Universitario de Alicante, ISABIAL
                  address:
                     name:Department of Medical Oncology, Hospital Universitario de Alicante, ISABIAL, Alicante, Spain
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Manuel Dómine
            affiliation:
                  name:Hospital Universitario Fundación Jiménez Díaz, Oncohealth Institute, Universidad Autónoma de Madrid
                  address:
                     name:Department of Medical Oncology, Hospital Universitario Fundación Jiménez Díaz, Oncohealth Institute, Universidad Autónoma de Madrid, Madrid, Spain
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Rosario García-Campelo
            affiliation:
                  name:A Coruña University Hospital
                  address:
                     name:Department of Medical Oncology, A Coruña University Hospital, A Coruña, Spain
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Manuel Cobo
            affiliation:
                  name:Hospital Universitario Málaga Regional y Virgen de la Victoria, IBIMA
                  address:
                     name:Medical Oncology Department, Hospital Universitario Málaga Regional y Virgen de la Victoria, IBIMA, Málaga, Spain
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Enriqueta Felip
            affiliation:
                  name:Hospital Universitari Vall d’Hebron and Vall d’Hebron Institute of Oncology (VHIO)
                  address:
                     name:Lung Cancer Unit, Hospital Universitari Vall d’Hebron and Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Immunology, Immunotherapy
      issn:
         1432-0851
         0340-7004
      volumeNumber:68
Organization:
      name:Springer Berlin Heidelberg
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Catalan Institute of Oncology (ICO)
      address:
         name:Department of Medical Oncology, Catalan Institute of Oncology (ICO), Barcelona, Spain
         type:PostalAddress
      name:IDIBELL
      address:
         name:Clinical Research in Solid Tumors (CReST) Group, OncoBell Program, IDIBELL, Barcelona, Spain
         type:PostalAddress
      name:Hospital Universitario de Alicante, ISABIAL
      address:
         name:Department of Medical Oncology, Hospital Universitario de Alicante, ISABIAL, Alicante, Spain
         type:PostalAddress
      name:Hospital Universitario Fundación Jiménez Díaz, Oncohealth Institute, Universidad Autónoma de Madrid
      address:
         name:Department of Medical Oncology, Hospital Universitario Fundación Jiménez Díaz, Oncohealth Institute, Universidad Autónoma de Madrid, Madrid, Spain
         type:PostalAddress
      name:A Coruña University Hospital
      address:
         name:Department of Medical Oncology, A Coruña University Hospital, A Coruña, Spain
         type:PostalAddress
      name:Hospital Universitario Málaga Regional y Virgen de la Victoria, IBIMA
      address:
         name:Medical Oncology Department, Hospital Universitario Málaga Regional y Virgen de la Victoria, IBIMA, Málaga, Spain
         type:PostalAddress
      name:Hospital Universitari Vall d’Hebron and Vall d’Hebron Institute of Oncology (VHIO)
      address:
         name:Lung Cancer Unit, Hospital Universitari Vall d’Hebron and Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Ernest Nadal
      url:http://orcid.org/0000-0002-9674-5554
      affiliation:
            name:Catalan Institute of Oncology (ICO)
            address:
               name:Department of Medical Oncology, Catalan Institute of Oncology (ICO), Barcelona, Spain
               type:PostalAddress
            type:Organization
            name:IDIBELL
            address:
               name:Clinical Research in Solid Tumors (CReST) Group, OncoBell Program, IDIBELL, Barcelona, Spain
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Bartomeu Massuti
      affiliation:
            name:Hospital Universitario de Alicante, ISABIAL
            address:
               name:Department of Medical Oncology, Hospital Universitario de Alicante, ISABIAL, Alicante, Spain
               type:PostalAddress
            type:Organization
      name:Manuel Dómine
      affiliation:
            name:Hospital Universitario Fundación Jiménez Díaz, Oncohealth Institute, Universidad Autónoma de Madrid
            address:
               name:Department of Medical Oncology, Hospital Universitario Fundación Jiménez Díaz, Oncohealth Institute, Universidad Autónoma de Madrid, Madrid, Spain
               type:PostalAddress
            type:Organization
      name:Rosario García-Campelo
      affiliation:
            name:A Coruña University Hospital
            address:
               name:Department of Medical Oncology, A Coruña University Hospital, A Coruña, Spain
               type:PostalAddress
            type:Organization
      name:Manuel Cobo
      affiliation:
            name:Hospital Universitario Málaga Regional y Virgen de la Victoria, IBIMA
            address:
               name:Medical Oncology Department, Hospital Universitario Málaga Regional y Virgen de la Victoria, IBIMA, Málaga, Spain
               type:PostalAddress
            type:Organization
      name:Enriqueta Felip
      affiliation:
            name:Hospital Universitari Vall d’Hebron and Vall d’Hebron Institute of Oncology (VHIO)
            address:
               name:Lung Cancer Unit, Hospital Universitari Vall d’Hebron and Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Medical Oncology, Catalan Institute of Oncology (ICO), Barcelona, Spain
      name:Clinical Research in Solid Tumors (CReST) Group, OncoBell Program, IDIBELL, Barcelona, Spain
      name:Department of Medical Oncology, Hospital Universitario de Alicante, ISABIAL, Alicante, Spain
      name:Department of Medical Oncology, Hospital Universitario Fundación Jiménez Díaz, Oncohealth Institute, Universidad Autónoma de Madrid, Madrid, Spain
      name:Department of Medical Oncology, A Coruña University Hospital, A Coruña, Spain
      name:Medical Oncology Department, Hospital Universitario Málaga Regional y Virgen de la Victoria, IBIMA, Málaga, Spain
      name:Lung Cancer Unit, Hospital Universitari Vall d’Hebron and Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(289)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.26s.

LINK . SPRINGER . COM {}